IN2014DN03429A - - Google Patents

Info

Publication number
IN2014DN03429A
IN2014DN03429A IN3429DEN2014A IN2014DN03429A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A IN 3429DEN2014 A IN3429DEN2014 A IN 3429DEN2014A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A
Authority
IN
India
Prior art keywords
inhibitor
matrix
allergene
whereon
adsorbed
Prior art date
Application number
Inventor
Thomas Grunwald
WEBER Carsten B SCHMIDT
Original Assignee
Pls Design Gmbh
Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pls Design Gmbh, Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh filed Critical Pls Design Gmbh
Publication of IN2014DN03429A publication Critical patent/IN2014DN03429A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL 4 and/or IL 13 inhibitor and at least one allergene and a matrix wherein at least the inhibitor is solved or embedded or whereon at least the inhibitor is coated or adsorbed wherein the matrix is selected as to enable prolonged release of the inhibitor.
IN3429DEN2014 2011-11-23 2012-11-23 IN2014DN03429A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11075261.5A EP2596802A1 (en) 2011-11-23 2011-11-23 Pharmaceutical composition for treatment of allergic reactions
PCT/EP2012/004884 WO2013075846A1 (en) 2011-11-23 2012-11-23 Pharmaceutical composition for treatment of allergic reactions

Publications (1)

Publication Number Publication Date
IN2014DN03429A true IN2014DN03429A (en) 2015-06-05

Family

ID=47358079

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3429DEN2014 IN2014DN03429A (en) 2011-11-23 2012-11-23

Country Status (6)

Country Link
US (2) US20140335162A1 (en)
EP (1) EP2596802A1 (en)
CN (1) CN104039349A (en)
BR (1) BR112014012277A2 (en)
IN (1) IN2014DN03429A (en)
WO (1) WO2013075846A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
EP3970748B1 (en) * 2014-12-24 2024-07-24 NexImmune, Inc. Nanoparticle compositions and methods for immunotherapy
CN105727371B (en) * 2016-01-25 2019-04-09 北京天助畅运医疗技术股份有限公司 Ventral hernia repair material
PL3448391T3 (en) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN107669638B (en) * 2017-10-23 2020-05-22 华南理工大学 A kind of PEG-PCL-PEG triblock copolymer modified madecassoside liposome and its application
JP2023522676A (en) * 2020-04-22 2023-05-31 キンドレッド バイオサイエンシズ インコーポレイテッド IL4/IL13 receptor molecules for animals

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4137333A1 (en) 1991-11-13 1993-05-19 W Prof Dr Sebald THERAPEUTIC AGENTS THAT ARE ANTAGONISTS OR PARTIAL AGONISTS OF THE HUMAN INTERLEUKIN 4 OR CONTAIN THEM, HIL-4-MUTANT PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
HUP9902824A3 (en) 1996-06-14 2001-11-28 Bayer Corp Pittsburgh T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
AR015175A1 (en) 1997-10-03 2001-04-18 Macromed Inc BIODEGRADABLE POLYMERIC WATERPROOF COMPOSITION FOR DELIVERY OF A DRUG.
WO1999044583A2 (en) * 1998-03-02 1999-09-10 Applied Vaccine Technologies Corp. Methods and devices for modulating the immune response
CN1299272A (en) * 1998-03-02 2001-06-13 应用疫苗技术公司 Method and device for modulating the immune response
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
ES2382891T3 (en) 2000-05-26 2012-06-14 Immunex Corporation Use of IL-4R antibodies and their compositions
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE378427T1 (en) 2005-10-17 2007-11-15 Rina Netzwerk Rna Technologien METHOD FOR DETERMINING AN UNKNOWN PNS SEQENCE AND ITS USES
US7947648B2 (en) * 2006-01-11 2011-05-24 Aerovance, Inc. Methods for treating asthma in human and non human primates using IL-4 mutant compositions
MX350501B (en) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Vaccine nanotechnology.
EP2604628A3 (en) 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
US20110287100A1 (en) * 2009-01-28 2011-11-24 Sabine Desset-Brethes Galenic Formulations of Organic Compounds
JP5656370B2 (en) 2009-07-01 2015-01-21 キヤノン株式会社 Image processing apparatus, image processing system, image processing method, and program

Also Published As

Publication number Publication date
US20140335162A1 (en) 2014-11-13
US20180117143A1 (en) 2018-05-03
EP2596802A1 (en) 2013-05-29
WO2013075846A1 (en) 2013-05-30
BR112014012277A2 (en) 2019-09-24
CN104039349A (en) 2014-09-10

Similar Documents

Publication Publication Date Title
IN2014DN03429A (en)
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
CO6771409A2 (en) Substituted 1-benzylcycloalkylcarboxylic acids and their use
IN2014DN06501A (en)
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12012500632B1 (en) Pharmaceutical compositions comprising bi-1356 and metformin
EP3354640A3 (en) Mif inhibitors and their uses
PH12012502162A1 (en) Combination therapy
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
MX2011008171A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof.
BR112012032816A2 (en) controlled release pharmaceutical composition, and methods for reducing the dietary effect of a controlled release composition, reducing the amount of time required to achieve a stable state for metformin, to improve the bioavailability of a controlled release dosage form. matrix
UY31228A1 (en) ARILOXAZOLES REPLACED AND ITS USE
MX345777B (en) Bilayer tablet formulations.
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
BR112015011430A2 (en) composition for immediate and prolonged release
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CL2013001482A1 (en) Compounds derived from 3-methyl-7-oxo-4-thia-1-aza-bicyclo [3.2.0] heptane for use in inhibiting beta-lactamases produced by bacteria and restoring / enhancing the activity of antibiotics; and pharmaceutical composition that includes them.
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
CL2010000899A1 (en) N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04).
GEP201706680B (en) Catechol o-methyltransferase activity inhibiting compounds
UA59396U (en) Use of compositions of non-steroid anti-inflammatory drugs and caffeine as antiexudative agents